The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) is a huge mover today! About 247,779 shares traded hands. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has declined 36.52% since March 11, 2016 and is downtrending. It has underperformed by 41.98% the S&P500.
The move comes after 6 months negative chart setup for the $1.21B company. It was reported on Oct, 14 by Barchart.com. We have $30.63 PT which if reached, will make NASDAQ:PCRX worth $84.70 million less.
Analysts await Pacira Pharmaceuticals Inc (NASDAQ:PCRX) to report earnings on October, 25. They expect $0.14 earnings per share, up 40.00% or $0.04 from last year’s $0.1 per share. PCRX’s profit will be $5.14 million for 58.82 P/E if the $0.14 EPS becomes a reality. After $-0.02 actual earnings per share reported by Pacira Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -800.00% EPS growth.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Ratings Coverage
Out of 10 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 7 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 70% are positive. Pacira Pharmaceuticals has been the topic of 18 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has “Buy” rating given on Friday, January 29 by Bank of America. The firm has “Outperform” rating given on Thursday, August 20 by Wedbush. Mizuho maintained the shares of PCRX in a report on Tuesday, May 3 with “Buy” rating. The rating was initiated by BMO Capital Markets on Wednesday, June 29 with “Underperform”. The stock of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has “Buy” rating given on Tuesday, September 29 by Nomura. The firm has “Neutral” rating given on Monday, August 3 by Bank of America. The firm has “Buy” rating by Jefferies given on Monday, September 26. The rating was maintained by Brean Capital on Friday, February 26 with “Buy”. The stock has “Hold” rating given by Brean Capital on Friday, July 1. The rating was initiated by Mizuho on Tuesday, April 19 with “Buy”.
According to Zacks Investment Research, “Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc. is based in New Jersey.”
Insitutional Activity: The institutional sentiment increased to 1.34 in 2016 Q2. Its up 0.39, from 0.95 in 2016Q1. The ratio increased, as 41 funds sold all Pacira Pharmaceuticals Inc shares owned while 39 reduced positions. 36 funds bought stakes while 71 increased positions. They now own 39.74 million shares or 7.79% less from 43.10 million shares in 2016Q1.
Moreover, Gsa Limited Liability Partnership has 0.06% invested in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 29,900 shares. Svcs Automobile Association has invested 0% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Janney Montgomery Scott Lc holds 5,664 shares or 0.01% of its portfolio. Strs Ohio accumulated 160,000 shares or 0.02% of the stock. Alliancebernstein Ltd Partnership accumulated 0% or 61,930 shares. Healthcor Mgmt Limited Partnership last reported 0.46% of its portfolio in the stock. The Connecticut-based Paloma Prtn has invested 0.01% in Pacira Pharmaceuticals Inc (NASDAQ:PCRX). Tower Capital Ltd Liability Co (Trc) last reported 0.02% of its portfolio in the stock. Rothschild Asset Incorporated holds 0% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 6,962 shares. Princeton Alpha L P last reported 6,008 shares in the company. Westfield Mngmt Communications Ltd Partnership accumulated 0.37% or 1.33M shares. Swiss National Bank accumulated 0% or 61,900 shares. Fifth Third State Bank last reported 0% of its portfolio in the stock. Clearbridge Invests Limited has 0.04% invested in the company for 1.09M shares. Goldman Sachs Grp Inc Inc holds 0.01% of its portfolio in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) for 559,048 shares.
Insider Transactions: Since April 15, 2016, the stock had 0 buys, and 7 insider sales for $2.03 million net activity. 1,136 shares were sold by HASTINGS PAUL J, worth $53,335. Williams Kristen Marie sold $28,319 worth of stock. The insider Scibetta James S sold $1.13M. STACK DAVID M sold $679,800 worth of stock. Kronenfeld Mark A. sold 900 shares worth $42,255. $44,706 worth of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) shares were sold by Riker Lauren Bullaro. $46,950 worth of shares were sold by Brege Laura on Monday, June 6.
More recent Pacira Pharmaceuticals Inc (NASDAQ:PCRX) news were published by: Fool.com which released: “Why Pacira Pharmaceuticals, Inc. Shares Are Spiking 21% Today” on August 04, 2016. Also Fool.com published the news titled: “Pacira Pharmaceuticals Inc.’s Double-Digit Drop Explained” on May 02, 2016. Schaeffersresearch.com‘s news article titled: “Analyst Update: Himax Technologies, Inc., Pacira Pharmaceuticals Inc, and …” with publication date: September 26, 2016 was also an interesting one.
PCRX Company Profile
Pacira Pharmaceuticals, Inc., incorporated on December 22, 2006, is a specialty pharmaceutical company. The Firm is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. The Company’s primary focus lies in the development of non-opioid products for postsurgical pain control. The Company’s lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company makes for its commercial partners, as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.